Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Let me conclude by saying that I'm pleased with our continued execution and I am proud of the leverage we're showing on our bottom line as we navigate the end of our business model transition |
| As we discussed on today's call, we started out our fiscal 2024 with a good quarter and once again delivered strong profitable growth |
| So I'm excited about the products we have, and really just over time is about scaling and making sure that we've got the right selling motions and sales coverage in the region |
| So we exited Q1 with very strong backlog |
| And we're well on our way to delivering those products |
| That said, we expect our SaaS growth metrics to improve as we exit the year, and we are pleased with our start to 2024 |
| I am encouraged by Q1 because we signed one of our last remaining large SaaS transitions, but more importantly, we saw meaningful contribution from our long-term growth drivers |
| I was also pleased to see a strong order from business services |
| In Q1, our new logo team posted a strong start to the year |
| And as I said in response to one of the past questions, a good point, just to clarify it again or reemphasize it, for these customers that are actively engaged in working with us post end of life in December, we are continuing to be a great partner to them, support them, and make sure we've got a great roadmap ahead |
| We've got great products and we've got a really good High Tech team, so I think they're set up to have a great year |
| And I'm very optimistic about this segment of the business as we look forward to the second half |
| And it's nice to start the year with that team posting a great quarter and see that there's still a meaningful opportunity on the new logo side |
| Model N will be instrumental in supporting these new launches, while also delivering several operational improvements, resulting in a strong ROI when the system is fully deployed |
| In Life Sciences, we also continue to see solid growth within our customer base led by new products that we're releasing |
| But certainly in terms of how they're partnered with us, they're really good about their pharma business, and we have a good pipeline that differentiates them from some of their other partners in the industry |
| Some customers certainly have robust pipelines and a unique growth opportunity in front of them |
| This helps us to improve our user experience and empowers customers to streamline user procedures |
| The adoption of Engage at Novartis demonstrates this new product's ability to help companies be more successful with their Model N investments while also improving overall operational excellence |
| And between that and the standard enablement we're doing with our sales force, I'm excited about this product I'm sure it will make a difference, particularly in these segments of the sector where margins are particularly region |
| So I think it's going to be very well received |
| And we're also strong partnered [Technical Difficulty] with that in the back to move forward |
| And we certainly see that with some of the new logos posted in Q1 and we have a good pipeline as we look forward this year |
| And then in terms of as I look at our pipeline this year, one of the things that I'm encouraged about you see it in our reported results, we are expecting to have nice contribution from new logos as well as our customer base |
| We are getting through the final stages of our business model transformation while at the same time still driving top-line growth, margin improvement and strong free cash flow |
| To summarize, Q1 was a strong start to fiscal 2024 and we continue to execute well |
| Finally, as mentioned, Q1 was a very strong quarter from a free cash flow standpoint as trailing 12 months free cash flow increased to $43 million from $23 million last quarter |
| Subscription revenue increased by 8% to $47.7 million, while professional services revenue grew by 6% to $15.8 million and both were above guidance |
| Looking specifically at our financial results, for the first quarter, total revenue grew 7% to $63.5 million, which exceeded the high end of our guidance range driven by upside on both subscription and professional services revenue |
| I was particularly pleased by our free cash flow performance which hit $43.5 million for the trailing 12 months ending Q1 and was up 172% on a year-over-year basis |
| Statement |
|---|
| This was slightly below our guidance due to some variance on below the line items including interest income and foreign exchange |
| We did have a little bit of pressure on the year-over-year growth in Q1, and we expect that to be an even more difficult comparison in Q2 |
| However, this quarter, we're having a little bit of a challenge with a small handful of projects that we can't get underway |
| So first of all, on the macro environment, I think we were one of the first companies in our space in our fiscal Q2 last year to callout some deal elongation cycles of delayed SaaS transitions and a little bit softness in discretionary spend |
| As we discussed on last call, we are facing difficult comparisons for our SaaS metrics over the first two to three quarters of this year due to SaaS transition activity last year |
| Joe, can you hear me? I've just been told we're having some audio issues |
| For a second year in a row, supply chain disruption emerged as one of the top obstacles across all industries |
| And finally, pharmaceutical executives do not see the pace of regulatory change slowing down anytime soon |
| So I would say that the backdrop has not deteriorated |
| And so new logo did suffer a bit in terms of investments in 2021 and 2022 |
| And so we've had a few delays in Q2 |
| As a result, the second quarter is typically the low watermark for adjusted EBITDA margin during the year |
| And so it's a pretty tough comp for Q2 |
| We had to make some difficult trade-offs as a result of that |
| That's not to say we're not excited about the High Tech business |
| We are hearing from customers they don't know what the pipeline is going to bring, and so they're kind of delaying new tech decisions |
| Next quarter, our fiscal Q2 is expected to be the most difficult comparison |
| And so it's basically some timing issues that we think we can fix over the course of Q3 and Q4 |
| We just have a little bit of a timing issue in Q2 here |
| And think of this as an industry gold copy of the payers and the providers and the different purchasing programs that they're eligible to participate in with the manufacturers solves another big pain point as well |
Please consider a small donation if you think this website provides you with relevant information